Get the Stockscreener App
49.15
6.99%
3.21
Pre-market:
50.13
0.98
+1.99%
Overview
News
Price History
Option Chain
Why NVO Down?
Discussions
Forecast
Stock Split
Dividend History
Novo Nordisk Adr stock is traded at $49.15, with a volume of 27.29M.
It is up +6.99% in the last 24 hours and down -13.67% over the past month.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
See More
Previous Close:
$45.94
Open:
$47.07
24h Volume:
27.29M
Relative Volume:
1.80
Market Cap:
$166.62B
Revenue:
$46.69B
Net Income/Loss:
$15.29B
P/E Ratio:
14.32
EPS:
3.4329
Net Cash Flow:
$9.25B
1W Performance:
+1.87%
1M Performance:
-13.67%
6M Performance:
-25.27%
1Y Performance:
-54.95%
1-Day Range:
$47.05
$49.42
1-Week Range:
$45.15
$49.56
52-Week Range:
$45.05
$112.52
Novo Nordisk Adr Stock (NVO) Company Profile
Name
Novo Nordisk Adr
Sector
Industry
Phone
-
Address
-
Compare NVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
49.15 | 204.13B | 46.69B | 15.29B | 9.25B | 3.4329 |
|
LLY
Lilly Eli Co
|
988.62 | 865.16B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
193.83 | 453.94B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
225.17 | 386.54B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
130.50 | 244.07B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
90.95 | 215.32B | 63.90B | 19.05B | 13.05B | 7.5596 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-27-25 | Resumed | Jefferies | Underperform |
| Oct-01-25 | Upgrade | HSBC Securities | Hold → Buy |
| Sep-29-25 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Sep-16-25 | Upgrade | Rothschild & Co Redburn | Neutral → Buy |
| Sep-09-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-13-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Aug-05-25 | Downgrade | UBS | Buy → Neutral |
| Jul-31-25 | Downgrade | HSBC Securities | Buy → Hold |
| Jul-30-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-17-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Mar-13-25 | Upgrade | Kepler | Hold → Buy |
| Mar-03-25 | Downgrade | Stifel | Buy → Hold |
| Feb-12-25 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-06-25 | Upgrade | Bernstein | Underperform → Mkt Perform |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-12-24 | Initiated | BMO Capital Markets | Outperform |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Neutral |
| Dec-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-02-23 | Initiated | Argus | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-15-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-28-22 | Downgrade | UBS | Neutral → Sell |
| Jun-27-22 | Upgrade | Exane BNP Paribas | Underperform → Neutral |
| Jun-07-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-31-22 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-25-22 | Upgrade | Cowen | Market Perform → Outperform |
| Apr-12-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-16-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-25-22 | Downgrade | Liberum | Hold → Sell |
| Dec-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-17-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Jan-20-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jul-06-20 | Downgrade | BofA Securities | Buy → Neutral |
| May-11-20 | Downgrade | UBS | Buy → Neutral |
| May-04-20 | Initiated | Cowen | Market Perform |
| Mar-16-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-20 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-18-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-17-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-30-19 | Downgrade | Jefferies | Hold → Underperform |
| Jun-20-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-11-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Apr-29-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-29-19 | Initiated | Exane BNP Paribas | Outperform |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Dec-29-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-06-17 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-01-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-25-17 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Sep-06-17 | Upgrade | BofA/Merrill | Underperform → Neutral |
View All
Novo Nordisk Adr Stock (NVO) Latest News
Novo Nordisk Rises Despite Metsera Loss, Slashes Wegovy Price In India - Benzinga
Even With Pricing and Competitive Pressure, Novo Nordisk's Portfolio Warrants a Wide Moat - Morningstar
Eli Lilly, Novo Nordisk Make Weight-Loss Drugs More Affordable Via Medicare, Medicaid, TrumpRx - Sahm
Novo Nordisk ADR earnings missed by $0.09, revenue fell short of estimates - Investing.com
Trump Administration's Weight-Loss Drug Deal Is Sending This Novo Nordisk Rival Surging: Momentum Score Spikes - Sahm
Can Novo Nordisk A s (b Shares) Adrhedged stock rebound after recent weaknessRecession Risk & Real-Time Volume Triggers - Fundação Cultural do Pará
Pfizer To Raise Metsera Bid After Court Denies Attempt To Block Rival Deal - Sahm
Novo Nordisk ADR earnings beat by $3.72, revenue topped estimates - Investing.com South Africa
Will Novo Nordisk A s (b Shares) Adrhedged stock gain from strong economyExit Point & Trade Opportunity Analysis - fcp.pa.gov.br
Ozempic Maker Novo Nordisk Trims Growth Outlook For Obesity Drugs - Sahm
Wegovy maker Novo Nordisk cuts guidance again but Medicare pricing deal uplifts investors - The Globe and Mail
Novo Nordisk ADR earnings beat by $3.72, revenue topped estimates By Investing.com - Investing.com Nigeria
$NVO Last opportunity! for NYSE:NVO by alexei_erchov - TradingView
Novo, Pfizer Are Battling To Buy The Future Of Weight-Loss — But Viking Already Owns It - Sahm
Pfizer Accuses Novo Nordisk Of Antitrust Violations In Metsera Takeover Battle - Sahm
Bengals-Bears game today: Chicago Bears outlast Cincinnati Bengals for wild 47-42 win on Williams' TD pass to Loveland - ABC7 Chicago
Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless' - Sahm
Will Novo Nordisk A s (b Shares) Adrhedged stock deliver strong dividend growthExit Point & Smart Investment Allocation Tips - fcp.pa.gov.br
Can Novo Nordisk A s (b Shares) Adrhedged stock outperform in 2025 bull marketJuly 2025 Chart Watch & Fast Momentum Entry Tips - fcp.pa.gov.br
P/E Ratio Insights for Novo Nordisk - Sahm
Options Corner: A Reliable Quant Signal Just Flashed Again For Pharma Giant Novo Nordisk - Sahm
Novo Nordisk to Convene Extraordinary General Meeting for Board Election - The Globe and Mail
Novo Nordisk Announces Extraordinary General Meeting for Board Elections - The Globe and Mail
Multi asset correlation models including Novo Nordisk A s (b Shares) Adrhedged2025 Big Picture & Accurate Entry and Exit Point Alerts - newser.com
J.P. Morgan Reaffirms Their Buy Rating on Novo Nordisk (0QIU) - The Globe and Mail
Novo Nordisk Stock Is Falling Friday: What's Driving The Action? - Sahm
Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs? - Sahm
Trump’s Ozempic pledge is nothing new, says Nordnet economist - medwatch.com
Trump-Induced Volatility Aside, Novo Trades Cheap While Patents Protect Its Profits Until 2032 - Sahm
What's Driving the Market Sentiment Around Novo Nordisk AS? - Sahm
Hims & Hers Stock's 150% Surge Is All Fundamentals—No Novo, No Problem - Sahm
Novo Nordisk Adr Stock (NVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.73%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):